Brown Advisory Inc. Sells 10,477 Shares of Hologic, Inc. (NASDAQ:HOLX)

Brown Advisory Inc. trimmed its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 14.3% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 62,812 shares of the medical equipment provider's stock after selling 10,477 shares during the period. Brown Advisory Inc.'s holdings in Hologic were worth $3,880,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its stake in Hologic by 22.3% in the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock valued at $113,000 after acquiring an additional 335 shares during the last quarter. SG Americas Securities LLC boosted its stake in Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock valued at $594,000 after acquiring an additional 5,172 shares during the last quarter. Groupama Asset Managment boosted its stake in Hologic by 63.4% in the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock valued at $3,918,000 after acquiring an additional 21,037 shares during the last quarter. Proficio Capital Partners LLC purchased a new position in Hologic in the fourth quarter valued at about $4,215,000. Finally, Signaturefd LLC boosted its stake in Hologic by 34.5% in the fourth quarter. Signaturefd LLC now owns 2,940 shares of the medical equipment provider's stock valued at $212,000 after acquiring an additional 754 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent research reports. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Royal Bank Of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley dropped their price target on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Raymond James Financial restated an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Stephens dropped their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $78.75.

Insider Activity at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director directly owned 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is owned by insiders.

Hologic Price Performance

NASDAQ HOLX traded down $1.13 on Friday, hitting $65.72. The stock had a trading volume of 1,776,763 shares, compared to its average volume of 2,391,464. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. The company has a market capitalization of $14.65 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 2.41 and a beta of 0.55. The firm has a 50-day moving average of $61.55 and a 200-day moving average of $63.48.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same period in the prior year, the company posted $1.03 EPS. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.